Moderna MRNA Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$3.19B-13.2% | -$2.82B+9.4% | -$3.12B-7.3% | -$2.9B+13.5% | -$3.36B+5.7% | ||
| $235M+9.3% | $215M+3.4% | $208M0.0% | $208M+8.3% | $192M+1.6% | ||
| $472M-2.3% | $483M+1.9% | $474M+2.8% | $461M+4.1% | $443M+3.3% | ||
| $10M+106% | -$156M+69.0% | -$503M-337% | -$115M-35.3% | -$85M+84.8% | ||
| —— | —— | -$78M+50.6% | -$158M+6.0% | -$168M-102% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| -$161M-5.2% | -$153M+26.4% | -$208M-2,700% | $8M+104% | -$188M-29.7% | ||
| —— | —— | $4M-96.7% | $120M+1,600% | -$8M-110% | ||
| -$81M-5.2% | -$77M+26.0% | -$104M-15.6% | -$90M-50.0% | -$60M+1.6% | ||
| —— | —— | -$154M+70.2% | -$517M-18.9% | -$435M+0.9% | ||
| -$23M-9.5% | -$21M— | —— | —— | —— | ||
| —— | —— | —— | —— | -$47M+9.6% | ||
| —— | —— | —— | —— | —— | ||
| $137M-28.6% | $192M-71.6% | $675M-14.9% | $793M-18.4% | $972M-7.5% | ||
| $5.35B-7.2% | $5.77B-5.6% | $6.11B-1.4% | $6.2B+7.8% | $5.75B-11.9% | ||
| $2.27B-3.7% | $2.35B-12.9% | $2.7B-10.8% | $3.03B-10.2% | $3.37B-15.0% | ||
| —— | —— | —— | —— | $10M— | ||
| $1.19B-40.4% | $1.99B— | —— | —— | —— | ||
| —— | $600M+33.3% | $450M+50.0% | $300M+100% | $150M— | ||
| $51M+45.7% | $35M+16.7% | $30M-16.7% | $36M-33.3% | $54M-18.2% | ||
| —— | —— | —— | —— | —— | ||
| —— | $22M+33.3% | $16.5M+50.0% | $11M+100% | $5.5M— | ||
| $607M+2.2% | $594M+4,469% | $13M-45.8% | $24M-51.0% | $49M-16.9% | ||
| $3M+50.0% | $2M+100% | $1M0.0% | $1M— | —— | ||
| $283M-57.6% | $668M— | —— | —— | —— | ||
| —— | $10M-25.9% | $13.5M-20.6% | $17M-17.1% | $20.5M-14.6% | ||
| —— | $26M-62.2% | $68.75M-38.3% | $111.5M-27.7% | $154.25M-21.7% | ||
| —— | —— | —— | —— | -$47M+9.6% | ||
| -$23M-9.5% | -$21M— | —— | —— | —— | ||
| -$161M-5.2% | -$153M+26.4% | -$208M-2,700% | $8M+104% | -$188M-29.7% | ||
| -$40M-5.3% | -$38M— | —— | —— | —— | ||
| $59M-11.9% | $67M-8.2% | $73M-5.2% | $77M-11.5% | $87M-8.4% | ||
| $235M+9.3% | $215M+3.4% | $208M0.0% | $208M+8.3% | $192M+1.6% | ||
| -$81M-5.2% | -$77M+26.0% | -$104M-15.6% | -$90M-50.0% | -$60M+1.6% | ||
| —— | —— | —— | —— | $10M— | ||
| $4.36B-21.6% | $5.56B+0.3% | $5.55B+1.8% | $5.45B-8.0% | $5.92B+6.5% | ||
| $2.27B-3.7% | $2.35B-12.9% | $2.7B-10.8% | $3.03B-10.2% | $3.37B-15.0% | ||
| $20M+11.1% | $18M-10.0% | $20M+42.9% | $14M+100% | $7M-30.0% | ||
| —— | $22M+33.3% | $16.5M+50.0% | $11M+100% | $5.5M— | ||
| $51M+45.7% | $35M+16.7% | $30M-16.7% | $36M-33.3% | $54M-18.2% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | $26M-62.2% | $68.75M-38.3% | $111.5M-27.7% | $154.25M-21.7% | ||
| —— | —— | -$2.96B+22.1% | -$3.79B+12.3% | -$4.33B+0.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Moderna generate?
- Moderna (MRNA) generated -$3.4B in operating cash flow over the trailing twelve months.
- What is Moderna's free cash flow?
- After $137.0M of capital expenditures, Moderna's free cash flow was -$3.6B over the trailing twelve months, up 16.3% year over year.
- Where does Moderna's cash flow data come from?
- Every line is extracted from Moderna's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
